Stay updated on Isatuximab Combo in High-Risk Myeloma Clinical Trial
Sign up to get notified when there's something new on the Isatuximab Combo in High-Risk Myeloma Clinical Trial page.

Latest updates to the Isatuximab Combo in High-Risk Myeloma Clinical Trial page
- Check6 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a note regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference5%
- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference4%
- Check28 days agoChange DetectedThe page has updated the date for the Post-Transplant Maintenance Therapy with Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients from December 18, 2024, to June 6, 2025, and has revised the version number from v2.16.2 to v2.16.3.SummaryDifference2%
- Check35 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.3%
- Check42 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an updated version number from v2.16.0 to v2.16.1.SummaryDifference6%
- Check49 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference1.0%
Stay in the know with updates to Isatuximab Combo in High-Risk Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Isatuximab Combo in High-Risk Myeloma Clinical Trial page.